Fibrotic Diseases

Seprase or fibroblast activation protein (FAP) plays an important role in fibrotic diseases. Seprase (FAP) is not only an important fibrosis marker but also a potential therapeutic target. Alfa Cytology has extensive experience in the development of targeted seprase (FAP) therapies for fibrotic diseases and aims to provide a one-stop solution for biotech and biopharmaceutical companies globally.

Introduction to Seprase (FAP)-Targeted Therapeutics for Fibrotic Diseases

Seprase (FAP), a 97 kDa type II transmembrane serine protease, is a member of the prolyl peptidase family containing dipeptidyl peptidase IV (DPPIV, CD26). It participates in wound healing, inflammation, tissue remodeling, and fibrosis.

Fig. 1 A Vaccine Against Fibroblast Activation Protein Improves Murine Cardiac Fibrosis by Preventing the Accumulation of Myofibroblasts. (Yoshida, S., et al. 2025)

Seprase (FAP) is predominantly expressed under pathological conditions, especially in injured tissues and tumor-associated fibroblasts. Seprase (FAP) promotes remodeling and deposition of the extracellular matrix (ECM) and accelerates the development of fibrosis. Therefore, seprase (FAP) is not only an important fibrosis marker but also a therapeutic target.

Seprase (FAP)-Targeted Drug Development for Fibrotic Diseases

The following are drugs development that target seprase or fibroblast activation protein (FAP), including but not limited to:

Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

At Alfa Cytology, we are committed to advancing the development of innovative therapies and diagnostics for fibrotic diseases based on seprase or fibroblast activation protein (FAP) targets. Our platform provides comprehensive solutions for a wide range of fibrotic diseases.

Diverse Fibrotic Diseases

Multiple Therapeutics Development Services

As a one-stop solution, we not only provide development services for a wide variety of drugs but also have specialized experimental platforms for efficacy evaluation, DMPK/ADME studies, and safety assessment. To further expedite the drug development process, we provide a variety of preclinical animal models necessary for drug development.

Based on cutting-edge technology combined with our deep knowledge of the seprase (FAP) pathway, we assure effective targeted therapeutic development services. Alfa Cytology provides a one-stop service for seprase (FAP)-targeted drug development. Whatever your specific needs may be, feel free to get in touch with us, and we will provide further information along with pricing details.

For research use only.